ArticleAnnals of clinical and translational neurology2024
Retina as a potential biomarker for the early stage of Alzheimer's disease spectrum.
Article in Annals of clinical and translational neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The Visual System in Alzheimer's Disease: A Multilevel Review of Pathology, Monitoring, and Intervention.Vision (Basel, Switzerland) · 2026Review
- A timeline of structural and functional consequences to ipRGCs in a mouse model of Alzheimer's disease.Neurobiology of aging · 2026Article
- Brain-body interactions in systemic diseases: a survey from an imaging perspective.MedScience · 2026Review
- The Retina as a Proxy for Brain Neurodegeneration: A Narrative Review on OCT-Based Retinal Imaging in the Early Detection of Alzheimer's and Parkinson's Disease.Journal of imaging · 2026Review
- Assessing outer retinal and choroidal changes in scd: potential for high-risk screening using SS-OCTA.Translational psychiatry · 2025Article
- Retinal microvascular alterations in motoric cognitive risk syndrome: an OCT angiography study.International ophthalmology · 2025Observational
- Cognition-Eye-Brain Connection in Alzheimer's Disease Spectrum Revealed by Multimodal Imaging.Journal of magnetic resonance imaging : JMRI · 2025Article
- Non-Invasive Retinal Biomarkers for Early Diagnosis of Alzheimer's Disease.Biomedicines · 2025Review
- Retinal vascular biomarkers in mild cognitive impairment and Alzheimer's disease: a comprehensive review and meta-analysis.Alzheimer's & dementia (Amsterdam, Netherlands)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo characterize the retinal microvasculature and structure in subjective cognitive decline (SCD) and identify the potential biomarker for the early stage of the Alzheimer's disease (AD) spectrum.
methodsIn this study, 35 patients with SCD, 36 with cognitive impairment, and 29 with normal cognition (NC) were enrolled. Optical coherence tomography angiography was employed to assess retinal vascular density, fovea avascular zone area, and retinal thickness. The parameters reflecting retinal perfusion and structure were compared among the three groups. In addition, the association between retinal parameters, cerebral blood flow (CBF), and peripheral blood biomarkers in the SCD stage was analyzed.
resultsThe superficial vascular complex (SVC) vascular density in the macula and retinal nerve fiber layer thickness in the peripapillary were significantly reduced in individuals with SCD compared to NC. Furthermore, there was a positive correlation between macular ganglion cell complex thickness and CBF in SCD.
interpretationThe retinal microvasculature and structure exhibit alterations in individuals with SCD. Macular ganglion cell complex thickness demonstrates correlations with cerebral perfusion. The retina holds potential as a novel biomarker for early detection of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.